Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
Abroad (travel likely)RecruitingPHASE2
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hospital of the University of Munich, Munich, Germany
Contact: Study coordinator (Enrico N De Toni, MD) · enrico.detoni@med.uni-muenchen.de · +49 (0)894400-0Contact: Principal Investigator (Enrico N De Toni, MD)Klinikum Rechts der Isar of the Technical University Munich, Munich, Germany
Würzburg University Hospital, Würzburg, Germany